Resources Repository
-
ArticlePublication 2021COVID-19 Infodemic: Twitter vs. Facebook
The global spread of COVID-19 is affected by the spread of related misinformation – the …
The global spread of COVID-19 is affected by the spread of related misinformation – the so-called COVID-19 infodemic – that makes populations more vulnerable to the disease through resistance to mitigation efforts. This article analyzes the prevalence and diffusion of links to low-credibility content about the COVID-19 pandemic across Twitter and Facebook. They characterize cross-platform similarities and differences in popular sources, diffusion patterns, influencers, coordination, and automation. Comparing the two platforms, authors found divergence among…
Decision Psychology | Global | Policy/Regulation | Preferences/Values | Infectious Diseases | Social Determinants | Culture/Society | Health/Medicine | Science/Technology | North America -
ArticlePublication 2021Distributional Health and Financial Consequences of Increased Cigarette Tax in Iran: An ECEA
This study examines the potential impact of a tax-induced cigarette price increase on financial and …
This study examines the potential impact of a tax-induced cigarette price increase on financial and health outcomes across different socioeconomic groups in Iran. Using pooled cross-sectional data from Household Income and Expenditure Surveys (2002–2017) and population data from Iran in 2019, an extended cost-effectiveness analysis (ECEA) methodology is employed to model the effects of a hypothetical increase in cigarette tax. The analysis evaluates health benefits, health expenditures averted, additional tax revenues generated, changes in household…
Health Outcomes | Middle East & North Africa | Policy/Regulation | Mathematical Models | Cost-Effectiveness Analysis | Health/Medicine -
EditorialPublication 2020Waiting for Certainty on COVID-19 Antibody Tests — At What Cost?
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation …
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation policy to reduce COVID-19 transmission. For example: Could we screen for serologic antibodies as a proxy for possible immunity and identify people who could return to the workplace with less severe mitigation measures? The authors acknowledge the uncertainties raised by many policy actors, including the WHO, such as, "Do antibodies confer immunity and, if so, for how long? How accurate is…
Probability/Bayes | Global | Policy/Regulation | Test Performance | Technology Assessment | Infectious Diseases | Health Systems | Government/Law | Health/Medicine | North America -
ArticlePublication 2017Extended Cost-Effectiveness Analyses of Cardiovascular Risk Factor Reduction Policies
This chapter summarizes lessons learned from three extended cost-effectiveness analyses (ECEAs) conducted on cardiovascular disease …
This chapter summarizes lessons learned from three extended cost-effectiveness analyses (ECEAs) conducted on cardiovascular disease (CVD) risk factor reduction policies, specifically highlighting new insights into the differential impacts of well-established CVD prevention interventions. Tobacco taxation, salt reduction, and primary prevention of CVD in high-risk individuals remain widely regarded as best buys in global noncommunicable disease policy, and the ECEAs confirm the findings of previous CEAs, namely, that these interventions will likely result in large health…
Priority Setting/Ethics | Global | Chronic Disease/Risk | Evidence Synthesis | Cost-Effectiveness Analysis | Health/Medicine -
Resource PackPublication, Teaching Resource 2024Resource Pack: BCA in Low- and Middle-Income Countries
This resource pack, curated by the Center for Health Decision Science, includes methods papers, case …
This resource pack, curated by the Center for Health Decision Science, includes methods papers, case studies, and reference case guidelines for conducting benefit-cost analyses in low- and middle-income countries. These resources will aid advanced students and experienced practitioners in preparing these analyses. Investing in global health and development requires making difficult choices about what initiatives to fund and what level of resources to devote to each initiative. Although benefit-cost analysis is a well-established and widely…
Priority Setting/Ethics | Global | Policy/Regulation | Preferences/Values | Decision Analysis | Benefit-Cost Analysis | Social Determinants | Economics/Finance | Health/Medicine | Graduate | Doctoral | Professional | Critical Thinking/Analysis -
Resource PackPublication, Teaching Resource 2024Resource Pack: Introduction to Benefit-Cost Analysis
This resource pack, curated by the Center for Health Decision Science, introduces the theory and …
This resource pack, curated by the Center for Health Decision Science, introduces the theory and practice of benefit-cost analysis. It is targeted towards advanced students as well as practitioners and those interested in teaching benefit-cost analysis. Benefit-cost analysis (also referred to as cost-benefit analysis) is a well-established and widely-used form of economic evaluation. It is designed to inform policy and other decisions by providing evidence on the consequences of alternative interventions. In benefit-cost analysis, all…
Priority Setting/Ethics | Global | Policy/Regulation | Preferences/Values | Decision Analysis | Benefit-Cost Analysis | Social Determinants | Climate/Environment | Economics/Finance | Government/Law | Health/Medicine | College | Graduate | Doctoral | Professional | Critical Thinking/Analysis -
ReportPublication 2019Top 10 Health Economics and Outcomes Research Trends
As governments and other payers struggle with provision of the best possible health outcomes at …
As governments and other payers struggle with provision of the best possible health outcomes at affordable costs, the field of health economics and outcomes research (HEOR) has experienced rapid growth. The International Society for Pharmacoeconomics Outcomes Research (ISPOR) produced the ISPOR 2019 Top 10 HEOR Trends which serves to outline the top 10 that the Society members identified that will be the most impactful during 2019. Development of this report included a comprehensive review and…
Health Outcomes | Global | Policy/Regulation | Social Determinants | Health Systems | Global Governance | Health/Medicine | Science/Technology -
OrganizationWeb Portal 2024Society for Benefit-Cost Analysis
The Society for Benefit-Cost Analysis (SBCA), founded in 2007, works to improve the theory and …
The Society for Benefit-Cost Analysis (SBCA), founded in 2007, works to improve the theory and practice of benefit-cost analysis and support evidence-based policy decisions. It addresses policy areas including public health, transportation, criminal justice, education, energy, environmental quality, homeland security, and poverty. Members include scholars and practitioners from around the world, who work in government, academia, nonprofits and private industry. Its members represent numerous disciplines such as economics, law, engineering, public policy, decision science, and…
Priority Setting/Ethics | Global | Policy/Regulation | Preferences/Values | Costing Methods | Benefit-Cost Analysis | Social Determinants | Environmental Health | Business/Industry | Climate/Environment | Economics/Finance | Energy/Engineering | Education/Labor | Food/Agriculture | Government/Law | Health/Medicine | Military/Defense | Science/Technology | Critical Thinking/Analysis -
ReportPublication 2017DCP3: Cardiovascular, Respiratory, and Related Disorders
This report from the World Bank is the fifth volume of the Disease Control Priorities, …
This report from the World Bank is the fifth volume of the Disease Control Priorities, Third Edition (DCP3) series. It addresses the disease burden of cardiovascular, respiratory, and related disorders (CVRDs), which account for more than half of global adult deaths, mostly in low- and middle-income countries. While CVRDs are mostly preventable or can be treated to reduce morbidity, such interventions are costly and require greater capacity to detect and treat early. When combined with…
Health Outcomes | Global | Chronic Disease/Risk | Costing Methods | Evidence Synthesis | Cost-Effectiveness Analysis | Social Determinants | Health Systems | Global Governance | Climate/Environment | Health/Medicine